君實生物(01877.HK)授出商業化許可 獲付款最高1,200萬美元
君實生物(01877.HK)公佈,與Hikma MENA FZE簽署《獨佔許可與商業化協議》,據此,公司將授予Hikma特瑞普利單抗注射液(產品代號「TAB001/JS001」)在約旦、沙特阿拉伯、阿聯酋、卡塔爾、摩洛哥、埃及等中東和北非地區共20個國家開發和商業化的獨佔許可,並可獲得合計最高達1,200萬美元的付款,外加銷售淨額近20%的階梯分成。
此外,公司還授予Hikma三項研發階段藥物在Hikma區域內一個或多個國家未來商業化權益的優先談判權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.